Home Newsfeeds Benchmark Reiterates Buy on Marcus, Maintains $20 Price Target

Benchmark Reiterates Buy on Marcus, Maintains $20 Price Target

Benchmark analyst Mike Hickey reiterates Marcus (NYSE:MCS) with a Buy and maintains $20 price target.

byBenzinga Newsdesk

March 6, 2023

1 minute read

Benchmark analyst Mike Hickey reiterates Marcus (NYSE:MCS) with a Buy and maintains $20 price target.

Analyst Ratings

The Latest Analyst Ratings for Huntsman

By Benzinga Insights

December 11, 12:00 PM

Huntsman (NYSE:HUN) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish…

HUN

Why US Drug Giant Bristol Myers Squibb Stock Trading Up On Monday

By Vandana Singh

June 3, 12:51 PM

Bristol Myers Squibb's KRYSTAL-12 study reveals Krazati's significant benefits over chemotherapy for KRASG12C-mutated NSCLC, improving progression-free survival and response rates.

BMY

Stephens & Co. Maintains Overweight on Baker Hughes, Lowers Price Target to $32

By Benzinga Newsdesk

July 21, 9:17 AM

Stephens & Co. analyst Cameron Lochridge maintains Baker Hughes (NASDAQ:BKR) with a Overweight and lowers the price target from $40 to $32.

BKR

Protolabs Sees Softer Start To 2024 Despite Hitting $500M Milestone Revenue In 2023: Details

By Akanksha Bakshi

February 9, 12:30 PM

Proto Labs, Inc. reported strong Q4 results, with revenue up 8.2% YoY and exceeding expectations. The company expects softer start to 2024, due to December 2023 and early January 2024 order levels being lower than historical periods.

PRLB

Benchmark Reiterates Buy on Marcus, Maintains $20 Price Target

Related Posts

The Latest Analyst Ratings for Huntsman

Why US Drug Giant Bristol Myers Squibb Stock Trading Up On Monday

Stephens & Co. Maintains Overweight on Baker Hughes, Lowers Price Target to $32

Protolabs Sees Softer Start To 2024 Despite Hitting $500M Milestone Revenue In 2023: Details